| | Business Summary | | Select
Therapeutics,
Inc.
a
development
stage
biopharmaceutical
company,
is
engaged
in
the
clinical
development
of
novel,
cell-based
therapeutic
products
employing
proprietary
tissue
engineering,
cell
growth
and
cell
targeting
technologies.
The
Company's
goal
is
to
provide
biopharmaceuticals
that
effectively
treat
and/or
cure
certain
cancers,
immunodeficiencies
and
infectious
diseases.
Organized
in
Canada
in
1996,
the
Company
is
now
headquartered
in
Woburn,
Massachusetts,
where
it
and
Cytomatrix,
LLC
(Cytomatrix)
have
formed
a
Joint
Venture,
Cell
Science
Therapeutics,
Inc.
(CST).
The
initial
focus
of
the
Joint
Venture
is
to
leverage
the
characteristics
of
a
proprietary
three-dimensional
(3-D)
cell
culture
system
to
expand
hematopoietic
stem
cells
and
reconstitute
the
cells
of
a
patient's
immune
system.
Select
Therapeutics,
Inc.
owns
50%
of
CST
and
has
a
six-month
option
starting
February
2002,
to
acquire
the
remaining
50%
for
9.7
million
shares. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | XZL,
a
development
stage
biopharmaceutical
company,
is
engaged
in
the
development
of
novel,
cell-based
therapeutic
products
employing
proprietary
tissue
engineering,
cell
growth
and
cell
targeting
technologies.
For
the
nine
months
ended
3/31/01,
revenues
totaled
$0
vs.
$171
thousand.
Net
loss
rose
53%
to
$4.7
million.
Results
reflect
the
sale
of
the
Sierra
Diagnostics
subsidiary.
Higher
losses
reflect
the
development
of
intellectual
property
resources. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Robert Bender, 53
Chairman,
Sec., Treasurer | $154K | Steve Peltzman, 55
CEO,
Director | -- | Michelle Guertin, 43
Controller | -- | | Dollar
amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/x/xzl.gif)